By Mill Chart
Last update: Sep 22, 2023
Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if REGENERON PHARMACEUTICALS (NASDAQ:REGN) is suited for quality investing. Investors should of course do their own research, but we spotted REGENERON PHARMACEUTICALS showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.
ChartMill utilizes a proprietary algorithm to assign a Fundamental Rating to every stock. This rating, ranging from 0 to 10, is computed daily by analyzing a variety of fundamental indicators and properties.
Overall REGN gets a fundamental rating of 7 out of 10. We evaluated REGN against 615 industry peers in the Biotechnology industry. REGN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. REGN has a decent growth rate and is not valued too expensively.
Our latest full fundamental report of REGN contains the most current fundamental analsysis.
Our Caviar Cruise screen will find you more ideas suited for quality investing.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
NASDAQ:REGN (12/8/2023, 7:13:09 PM)After market: 840.14 0 (0%)
Regeneron has been an excellent investment in recent years. Can that trend continue?
71% objective response rate, with 46% achieving a complete response or better after 11 months of median follow-up Data to be submitted to regulatory...
First dose-escalation results for REGN5668 (MUC16xCD28), a costimulatory bispecific, in combination with Libtayo® (cemiplimab) showed encouraging initial...
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
EyePoint Pharmaceuticals (EYPT) stock surges as their Phase 2 trial for EYP-1901, a therapy for wet age-related macular degeneration, meets main goals. Read more here.
The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to...